Enhancing Preoperative Iron Supplemenation in Lipoabdominoplasty: A Comparative Study of Ferric Carboxymaltose and Liposmal Iron.

Abstract

Preoperative anemia is a significant concern in plastic surgery, particularly in procedures such as lipoabdominoplasty, where intraoperative blood loss can impact postoperative recovery. Although oral iron supplementation is a common approach, its limited bioavailability and gastrointestinal intolerance often hinder effective anemia management. This study compares the efficacy of ferric carboxymaltose (FCM) (Ferinject) versus liposomal iron (SiderAL Forte) in optimizing preoperative iron levels and preventing postoperative anemia in patients undergoing 360-degree lipoabdominoplasty. A retrospective analysis was conducted on 44 female patients undergoing lipoabdominoplasty. Patients were divided into 2 groups: group A received oral liposomal iron (14 mg, twice daily) for 1 month preoperatively, and group B received a single intravenous dose of FCM (1000 mg) 72 hours before surgery. Hemoglobin, hematocrit, and ferritin levels were assessed preoperatively, on postoperative day 1, and on postoperative day 7. Statistical comparisons were performed using independent t tests and Pearson correlation analysis. Preoperative hemoglobin and hematocrit levels were comparable between groups. However, postoperative hemoglobin decline was significantly more pronounced in group A ( P < 0.05), whereas group B showed a better preservation of iron stores and faster hematologic recovery. Ferritin levels remained significantly higher in group B throughout the postoperative period ( P < 0.05). No patients required blood transfusions or exhibited symptoms of acute anemia. Intravenous FCM is a superior strategy for preoperative iron optimization in lipoabdominoplasty, ensuring better perioperative stability, faster recovery, and reduced anemia-related complications compared with oral liposomal iron. Integrating this approach into perioperative protocols could enhance surgical outcomes. Therapeutic, III.